INTRODUCTION
Since the introduction of cisplatin into clinical practice against human malignant neoplasms [1] , several metal complexes, including rhodium carboxylates, have been tested for antitumor activity [2] [3] [4] . The rhodium(ll) carboxylates have the common tetrabridged acetate structure with a short RhRh bond ( Figure ) , whose axial positions can be readily occupied by Lewis bases [5, 6] . The pharmacological evaluations of rhodium carboxylates (rhodium acetate, propionate and butyrate), have shown statistically significant activity against Ehrlich ascites carcinoma, melanoma B16, leukemia P388 and leukemia L1210 [2, 7, 8] . The activity was found to be in the order: acetate < propionate < butyrate; rhodium(ll) propionate having a more interesting therapeutic index. However, the researches involving these complexes have diminished, in part because of the demonstrated acute toxicity [9, 10] as well as the evident difficulty of aqueous solubilization of most of the compounds synthesized.
Recently, we reported a strategy for turning these compounds more water-soluble, by forming adducts with isonicotinic acid [11] , that allows more appropriate experimental investigation of the activity of rhodium carboxylates on tumor cells.
As an extension of these studies and as part of the pharmacological evaluation of rhodium(ll) carboxylates, we have studied the distribution of rhodium in mice Balb/c following the i.p. administration of the adduct of rhodium(ll) propionate and sodium isonicotinate.
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MATERIALS AND METHODS

Chemicals
The adduct of rhodium(ll) propionate and isonicotinic acid was prepared by the method previously described [11] . The Table 2 .
RESULTS
The results, presented in Table 1 The rhodium persisted in the majority of the tissues for at least six days, disappearing after this period. In liver, the metal remained more than twenty days. Table 1 indicates that the maximal rhodium concentration in the tissues was reached at 24-48 h, declining after this period. The blood, liver and kidney rhodium time data were fitted to a one-compartment model and the results are shown in Table 2 . The tissue half-life of rhodium is about 2-fold greater for liver than for kidney.
DISCUSSION
The interest in the potential antitumor activity of rhodium(ll) carboxylates has gained new strength in recent years. Several biological studies have been performed in vitro using tumor cell lines [11, 12] and in vivo with mice bearing tumors [10] , searching for more effective compounds. However, there (Table 2) with those published for cisplatin and carboplatin in mice [14] , we note that the blood half-life time (tl/2) of rhodium (33.6 h) is slightly shorter than that described for platinum in cisplatin (36.5 h) or carboplatin (49.5 h). Likewise, the t.,2 of rhodium in liver (149 h) is similar to that for platinum in cisplatin (133 h) and carboplatin (147 h). However, the t.,2 of rhodium in kidney (62.0 h) is shorter that for platinum in cisplatin (119 h) and carboplatin (94.9 h).
